2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. Blood Adv 2019 Dec 10;3(23):3945-3950
Date
12/04/2019Pubmed ID
31794603Pubmed Central ID
PMC6963245DOI
10.1182/bloodadvances.2019000931Scopus ID
2-s2.0-85076339236 (requires institutional sign-in at Scopus site) 16 CitationsAbstract
The American Society of Hematology (ASH) convened 5 guideline panels to develop clinical practice recommendations addressing 5 management areas of highest importance to individuals living with sickle cell disease: pain, cerebrovascular complications, pulmonary and kidney complications, transfusion, and hematopoietic stem cell transplant. Panels were multidisciplinary and consisted of patient representatives, content experts, and methodologists. The Mayo Clinic Evidence-Based Practice Center conducted systematic reviews based on a priori selected questions. In this exposition, we describe the process used by ASH, including the GRADE approach (Grades of Recommendations, Assessment, Development and Evaluation) for rating certainty of the evidence and the GRADE Evidence to Decision Framework. We also describe several unique challenges faced by the guideline panels and the specific innovations and solutions used to address them, including a curriculum to train patients to engage in guideline development, dealing with the opioid crisis, and working with indirect and noncomparative evidence.
Author List
Murad MH, Liem RI, Lang ES, Akl EA, Meerpohl JJ, DeBaun MR, Tisdale JF, Brandow AM, Lanzkron SM, Chou ST, Webb S, Mustafa RAAuthor
Amanda Brandow DO Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
HematologyHistory, 21st Century
Humans
United States
